Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) General Information

Description

Portfolio of small molecule acetyl co-A synthetase-2 inhibitor intended for treatment of cancers. The asset includes novel, potent and selective next generation ACSS2i as well as other ACSS2i compounds, including the clinical candidate known as MTB9655.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Yavne
  • Israel
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Corporate Office
  • Yavne
  • Israel

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)‘s full profile, request access.

Request a free trial

Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)‘s full profile, request access.

Request a free trial

Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) FAQs

  • Where is Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) headquartered?

    Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) is headquartered in Yavne, Israel.

  • What industry is Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) in?

    Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)’s primary industry is Buildings and Property.

  • Is Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) a private or public company?

    Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) is a Private company.

  • What is Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)’s current revenue?

    The current revenue for Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) is .

  • Who are Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)’s investors?

    Metabomed has invested in Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor).

  • When was Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) acquired?

    Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) was acquired on 23-Jan-2024.

  • Who acquired Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)?

    Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) was acquired by EpiVario.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process